Press Releases | K36tx

top of page

News Archive

Dec 3, 2024

PR Newswire

K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 15, 2023

PR Newswire

K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 15, 2023

PR Newswire

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Nov 8, 2023

Yahoo! Finance

K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough

June 28, 2023

Best Stocks

K36 Therapeutics Secures 70 Million in Funding for Groundbreaking Multiple Myeloma Treatment

June 28, 2023

Precision Medicine Online

K36 Therapeutics Raises $70M in Series B Financing

June 28, 2023

Fox5

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

June 28, 2023

Global Genes

K36 Therapeutics Raises $70 Million to Fund Clinical Proof of Concept of Rare Cancer Treatment

June 28, 2023

BioSpace

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

June 28, 2023

Tullahoma News

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

June 28, 2023

Boston Business Journal

Bristol Myers backs cancer startup K36 Therapeutics in $70M round

June 28, 2023

PR Newswire

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

April 12, 2023

K36 doses first patient in Phase l multiple myeloma therapy trial

Clinical Trials Area

April 11, 2023

PR Newswire

K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director

June 28, 2023

Precision Medicine Online

K36 Therapeutics Treats First Multiple Myeloma Patient in Phase I Trial of KTX-1001

December 9, 2021

Endpoints News

Atlas, F-Prime launch K36 Therapeutics to advance oncology molecule for elusive epigenetic target

December 9, 2021

Biocentury

F-Prime, Atlas back K36 with $30M to advance MM candidate

December 9, 2021

Biospace

Four Fresh-Faced Biopharmas Reel in Millions in Series A Funds

December 9, 2021

Fierce Biotech

K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis

December 9, 2021

PR Newswire

K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures

December 9, 2021

Precision Medicine Online

K36 Therapeutics Raises $30M in Series A Funds

December 9, 2021

Scrip

Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups

December 9, 2021

TrialSite News

K36 Therapeutics Launches with $30 Million Series A Financing to Advance Targeted Therapy for Multiple Myeloma

December 9, 2021

Global Genes

K36 Therapeutics Launches with $30 Million to Target Multiple Myeloma

December 9, 2021

PR Newswire

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

bottom of page